Azitra Inc (AZTR)

Azitra's stock has been impacted by NYSE American non-compliance notices due to not meeting minimum stockholders' equity requirements. The company reported a wider net loss for 2025 and a decrease in cash reserves, leading to a 'going concern' paragraph in its audit opinion. Azitra announced a private placement financing in March 2026, after denying a report of a direct offering in November 2025. The stock price has significantly declined over the past year.

Azitra, Inc.'s products and services are not typically subject to demand seasonality. Demand for its therapeutic candidates is primarily driven by the prevalence of targeted diseases and the success of clinical trials, not seasonal fluctuations.

Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology, utilizing microbial libraries and AI to develop therapies. Their product candidates include ATR-04 for cancer patients' rash, ATR-12 for Netherton syndrome, and ATR-01 for ichthyosis vulgaris. Azitra also has a joint development agreement with Bayer.

Azitra, Inc. is headquartered in Branford, Connecticut, and primarily focuses on developing therapies for the United States. The company intends to expand internationally through partnerships and distribution agreements.

Azitra's brand reputation has likely been negatively affected by NYSE American non-compliance notices and a significant stock price decline. The denial of a report about a $44 million direct offering also contributed to a stock drop. While clinical trials progress, financial and compliance challenges appear to be the dominant factors influencing its overall brand perception.

Azitra, Inc. has a diverse ownership structure including institutional investors, individual insiders, and the general public. Institutional investors own approximately 11.16% of the stock. Individual insiders hold a significant portion of the company's stock, with approximately 98.08% insider ownership. The general public holds approximately 95.2% of the shares. Shareholders have experienced substantial dilution in the past year.